GenomeWeb’s Pharmacogenomics Reporter discussed GeneDx’s decision to file for inter partes review (IPR) of 11 patents held by, or licensed to, Myriad Genetics. Turna Ray reports that IPR of these 11 patents would require the USPTO to determine whether or not prior art undermines certain patent claims. Sterne, Kessler, Goldstein & Fox filed these IPRs on behalf of GeneDx.

To read the full article, click here.